ADHD

Clinicians explore the complex relationship between ADHD medication and pregnancy, emphasizing individualized risk assessments for optimal maternal and child health.

A groundbreaking online ADHD assessment shows 78% agreement with clinician evaluations, enhancing access to mental health care for adults.

Allison Baker, MD, shared insights on supporting women before, during, and after pregnancy at the APSARD conference.

Explore key insights on ADHD treatment barriers and the long-term outcomes for adolescents diagnosed with the disorder.

Benjamin E. Yerys, PhD, shares clinical insights on the impact of the comorbidity at the APSARD Conference.

New research reveals midlife ADHD patients exhibit early Alzheimer disease biomarkers.

Poster discusses evidence-based strategies for managing adult ADHD, including medication guidelines and considerations for comorbid conditions.

Poster presented at the APSARD Annual Conference demonstrates the importance of genetic testing in ADHD.

Centanafadine demonstrates promising effects on ADHD symptoms, enhancing key neurotransmitters without increasing psychomotor activity, according to poster data.

A look at upcoming presentations at APSARD 2026, January 15-18.

Otsuka Pharmaceutical submits a new drug application for centanafadine for treatment of ADHD, showing significant efficacy across all age groups.

Hormonal fluctuations significantly influence ADHD symptoms in women, highlighting the need for tailored treatments and further research in this area.

Take a look at the long-term effects of stimulant medications on ADHD, specifically tolerance and its implications for treatment efficacy.

Discover how objective testing transforms ADHD diagnosis and treatment, enhancing accuracy and accessibility for adults in hybrid care settings.

Let's investigate the complexities of diagnosing and treating ADHD in older adults, highlighting its prevalence, comorbidities, and treatment challenges.

Misinformation about ADHD impacts treatment and self-perception. This Special Report clarifies misconceptions, promotes understanding, and supports informed care for individuals with ADHD.

Explore how placebo effects vary across psychiatric disorders, revealing significant symptom improvements, especially in major depressive disorder and generalized anxiety disorder.

Learn more about facets of pediatric ADHD with Stacy Doumas, MD, MBA

Justin Kei, MD, discusses relation of sex differences, lifestyle, and hormones with ADHD

Discover the latest insights on ADHD diagnosis and treatment, including new DSM-5 criteria and effective therapeutic strategies for diverse patient needs.

Cingulate's CTx-1301 shows promising phase 3 results for ADHD, offering effective once-daily dosing and potential FDA approval by 2026.

Discover how best to approach ADHD assessments and utilize tools such as the Mentavi Diagnostic Evaluation, which can help improve patient care and reduce stigma.

A reproductive psychiatrist discusses the implications of recent FDA announcements on medication use during pregnancy, emphasizing the importance of mental health for mothers and babies.

Cingulate's CTx-1301, a novel ADHD treatment, gains FDA review, promising rapid relief and sustained efficacy for patients.

New research reveals women with ADHD are diagnosed 5 years later than men, highlighting the need for improved awareness and early intervention.